As of Friday close, Intra-Cellular Therapies Inc.’s (NASDAQ:ITCI) stock was up $0.93, moving up 1.68 percent to $56.24. The average number of shares traded per day over the past five days has been 709,880 shares. 2 times new highs have been achieved over the past 5 days, with a -$2.37 fall in that time frame. In the last twenty days, the average volume was 624,215, while in the previous 50 days, it was 651,710.
Since last month, ITCI stock retreated -9.33%. Shares of the company fell to $54.94 on 08/18/23, the lowest level in the past month. A 52-week high of $67.05 was reached on 06/21/23 after having rallying from a 52-week low of $42.01. Since the beginning of this year, ITCI’s stock price has risen by 6.27% or $3.32, and marked a new high 11 times. However, the stock has declined by -16.12% since its 52-week high.
ITCI stock investors should be aware that Intra-Cellular Therapies Inc. (ITCI) stock had its last reported insider trading activity 12 days ago on Aug 07. Neumann Mark, the EVP, Chief Commercial Officer of the company, disposed of 55,300 shares for $58.79 on Aug 07. It resulted in a $3,251,087 divestment by the insider. Durgam Suresh K. sold 1,842 shares at an average price of $65.00 on Jul 17. The insider now owns 21,262 shares following the transaction. On Jun 14, SVP of Finance CFO Hineline Lawrence J. sold 81,854 shares at $63.97 apiece. The transaction was valued at $5,236,329.
Valuation Metrics
The stock’s beta is 1.11. Besides these, the trailing price-to-sales (P/S) ratio of 14.67, the price-to-book (PB) ratio of 8.88.
Financial Health
In the three months ended June 29, Intra-Cellular Therapies Inc.’s quick ratio stood at 7.10, while its current ratio was 7.60, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 92.70% percent. In the year ended June 29, EBITDA margin amounted to -105.06%, whereas operating margins totaled -54.30%. Based on annual data, ITCI earned $229.87 million in gross profit and brought in $250.31 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -40.20%. Return on equity (ROE) for the past 12 months was -28.60%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ITCI’s revenue rose 49.83% to $95.31 million during the quarter, while net income inched up to $110.79 million. While analysts expected Intra-Cellular Therapies Inc. to report -$0.59 quarterly earnings, the actual figure was -$0.45 per share, beating the consensus estimate by 23.70%. During the quarter, the company generated -$48.99 million in EBITDA. The liabilities of Intra-Cellular Therapies Inc. were 106.51 million at the end of its most recent quarter ended June 29, and its total debt was $17.99 million. The value of shareholders’ equity is $96.09 million.
Technical Picture
This quick technical analysis looks at Intra-Cellular Therapies Inc.’s (ITCI) price momentum. With a historical volatility rate of 20.24%, the RSI 9-day stood at 31.02% on 18 August.
With respect to its five-day moving average, the current Intra-Cellular Therapies Inc. price is down by -4.04% percent or -$2.37. At present, ITCI shares trade -9.41% below its 20-day simple moving average and +17.46% percent above its 100-day simple moving average. However, the stock is currently trading approximately -13.65% below its SMA50 and +23.14% above its SMA200.
Stochastic coefficient K was 7.38% and Stochastic coefficient D was 7.52%, while ATR was 1.78. Given the Stochastic reading of 18.30% for the 14-day period, the RSI (14) reading has been calculated as 33.01%. As of today, the MACD Oscillator reading stands at -1.38, while the 14-day reading stands at -2.17.
Analyst Ratings
Morgan Stanley launched its rating on Intra-Cellular Therapies Inc. (NASDAQ: ITCI) to an Overweight in a note to investors on April 20, 2023. Intra-Cellular Therapies Inc. (ITCI) has been rated Buy by analysts. According to 0 brokerage firms, ITCI is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Intra-Cellular Therapies Inc. stock as buy, with 11 recommending it as overweight.
With a median target price of $77.50, the current consensus forecast for the stock is $59.00 – $100.00. Based on these forecasts, analysts predict Intra-Cellular Therapies Inc. (ITCI) will achieve an average price target of $78.67.
